Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31415061.
- Also identified by DOI 10.1001/jamaoncol.2019.2963 and PMC identifier 6696731.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study analyzes the medical records of 47 721 patients with various cancer types with <i>POLE/POLD1</i> mutations to evaluate whether the mutations were associated with immunotherapy outcomes.